Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of INCB057643 Formulations in Healthy Participants
NCT06941077Phase 1Completed
- Sponsor
- Incyte
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of INCB-057643 in myelofibrosis (MF) and myelodysplastic syndromes (MDS) (4 cohorts), sponsored by Incyte. Primary endpoints: Maximum Observed Plasma Concentration (Cmax), Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-last) and 1 more. Started May 2025; status: completed.
02
Drugs
INCB-057643
03
Conditions
myelofibrosis (MF)myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT06941077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06941077.